|Bid||1.94 x 1800|
|Ask||1.95 x 900|
|Day's Range||1.86 - 1.96|
|52 Week Range||1.85 - 3.96|
|Beta (3Y Monthly)||1.40|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 18, 2017 - May 19, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||9.00|
ThermoDox® Phase III OPTIMA Study Fully Enrolled in August; First Pre-Planned Efficacy Analysis Expected in Mid-2019 GEN-1 Phase I/II OVATION 2 Study Enrolling.
LAWRENCEVILLE, N.J, Nov. 08, 2018 -- Celsion Corporation (NASDAQ: CLSN) announced today that the Company will host a conference call to discuss financial results for the.
NEW YORK, Oct. 25, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Median progression-free survival (PFS) in patients treated per protocol (n=13) was 24.3 months and was 17.1 months for the intent-to-treat population (n=18) for all dose cohorts, including three patients who dropped out of the study after 13 days or less, and two patients who did not receive full neoadjuvant chemotherapy (NAC) and GEN-1 cycles. The results from the OVATION I Study support continued evaluation of GEN-1 based on promising tumor response, as reported in the PFS data, and the ability for surgeons to completely remove visible tumor at debulking surgery.
Celsion Corporation (CLSN), an oncology drug development company, today announced that a program overview of the Company’s novel, immunotherapy agent GEN-1 was published in the peer-reviewed journal, Future Oncology. The article is co-authored by Premal H. Thaker, M.D., M.S., associate professor of obstetrics and gynecology at the Siteman Cancer Center at the Washington University School of Medicine in St. Louis, Mo. and principal investigator in Celsion’s GEN-1 development program. The publication outlines the DNA plasmid, gene-based concept and the key attributes supporting GEN-1’s mechanism of action characterized by local and persistent delivery of IL-12 and modulation of tumor microenvironment favoring immune stimulation.
Celsion Corporation (CLSN), an oncology drug development company, today announced that on September 28, 2018, the Compensation Committee of the Company's Board of Directors approved the grant of (i) inducement stock options (the “Inducement Option Grants”) to purchase a total of 164,004 shares of common stock and (ii) restricted stock grants (the “Inducement Stock Grants”) totaling 19,000 shares of common stock to three new employees. All awards have a grant date of September 28, 2018. Each of the Inducement Option Grants has an exercise price per share equal to $2.77, the closing price of Celsion’s common stock as reported by Nasdaq on September 28, 2018.
Celsion Corporation (CLSN), an oncology drug development company, today announced the appointment of Marianne Lambertson as Vice President of Communications and Investor Relations effective September 17, 2018. Ms. Lambertson most recently held the position of Vice President, Corporate Communications, Investor Relations/Public Relations at Verastem Oncology, a development-stage biopharmaceutical company.
Biotech were trending mostly sideways in the week ending Sept. 14 after posting weekly gains in the previous two weeks. Notwithstanding the overall muted sentiment, there was some activity in reaction ...
Celsion Corporation (CLSN), an oncology drug development company, today announced it has begun dosing patients in the recently initiated OVATION II Study, the Company's randomized, Phase I/II clinical trial of GEN-1, its DNA-based immunotherapy for the localized treatment of ovarian cancer as an adjuvant to chemotherapy current standard of care. GEN-1, designed using Celsion's proprietary TheraPlas platform technology, is an interleukin-12 (IL-12) DNA plasmid vector encased in a non-viral nanoparticle delivery system, which enables cell transfection followed by persistent, local secretion of the IL-12 protein. "In previous studies, GEN-1 was shown to be well tolerated at doses up to 79 mg/m2 with meaningful, dose-dependent, pro-immune clinical activity,” said Dr. Nicholas Borys, Celsion's senior vice president and chief medical officer. “The overall median progression-free survival (PFS) in the first OVATION Study recently reached 24 months among patients treated per protocol.
Celsion Corporation (CLSN), an oncology drug development company, today announced that it has reached its enrollment objective of 550 patients in the Company's pivotal, Phase III OPTIMA Study, a multinational, randomized, double-blind, placebo-controlled clinical trial of ThermoDox® in combination with radiofrequency ablation (RFA) for the treatment of patients with hepatocellular carcinoma (HCC), also known as primary liver cancer. The OPTIMA Study's design and statistical plan incorporates two pre-planned interim efficacy analyses by the study’s Data Monitoring Committee (DMC), and the first interim analysis is expected to occur in the first half of 2019.
NEW YORK, Sept. 05, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
Celsion Corporation (CLSN), an oncology drug development company, today announced it has received approval from the New Jersey Economic Development Authority’s (NJEDA) Technology Business Tax Certificate Transfer (NOL) program to sell the Company’s unused New Jersey net operating losses (NOLs) and R&D tax credits for the tax years 2011 to 2017. The exact percentage of NOL’s to be sold will be determined by the NJEDA after reviewing all qualified applications.
NEW YORK, NY / ACCESSWIRE / August 14, 2018 / Celsion Corporation (NASDAQ: CLSN ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 14, 2018 at 11:00 AM Eastern Time. ...
Zacks.com highlights: Rosehill Resources, Navios Maritime Partners, AMC Entertainment Holdings, Entercom Communications and Celsion
Biotech stocks came under pressure earlier in the week, weighed down by negative trial results, mixed FDA verdicts and overall pessimistic broader market sentiment, but recovered in the last two sessions. ...
While the first half did not turn out to be great for the biotech sector, the second half is expected to be much better. Here, we list four biotechs poised for a good run.